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Alopecia areata is an autoimmune condition where
activated, pro-inflammatory white blood cells (WBCs)
attack the hair follicles, resulting in hair loss. Migration
of these activated WBCs from the blood stream and
into the follicle tissue requires interaction between the
integrin, lymphocyte function-associated antigen-1
(LFA-1) on WBCs, and ICAM-1 on vascular endothelial
cells. High levels of active LFA-1 are uniquely expressed
on WBCs that are involved in autoimmune and inflam-
matory conditions. The natural biologic agent LtxA
(Leukothera) preferentially targets and depletes dis-
ease activated and malignant WBCs by binding to
active LFA-1. The experimental drug has demonstrated
significant therapeutic efficacy against autoimmune/
inflammatory conditions such as psoriasis and allergic
asthma in mouse models for these diseases. In addi-
tion, when injected into rodents, rhesus macaques,
and dogs, LtxA was demonstrated to be physio-
logically active, biologically specific, and extremely
well-tolerated. LFA-1 is an attractive target for therapy
because it is only normally present on WBCs and has
been shown to be activated and overexpressed on
WBCs that are responsible for autoimmune/inflamma-
tory conditions.
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Alopecia areata (AA) is a condition that is characterized by
damage to the hair follicles and subsequent loss of hair
(Hordinsky, 2013). Damage to the follicle tissue is caused
by activated, pro-inflammatory white blood cells (WBCs)
migrating into the hair follicles from the blood stream.
Accumulation of WBCs in the follicle tissue of patients with
AA has been described as a ‘‘swarm of bees’’ because of the
appearance of the cells surrounding the follicles. These
activated WBCs consist of at least T cells, NK cells,
eosinophils, and mast cells (Elston et al., 1997; Gilhar et al.,
1997; Wasserman et al., 2007; Ito and Tokura, 2014; Santos
et al., 2015).
THE GREAT MIGRATION
Migration into and accumulation of the activated WBCs in the
hair follicle requires the beta-2 integrin lymphocyte function-
associated antigen-1 (LFA-1). LFA-1, composed of the two
polypeptide chains CD11a and CD18, is present exclusively
on the surface of WBCs and can exist is at least two functional
states, an active and an inactive state (Hogg et al., 1992;
Kinashi, 2005). In the active state, LFA-1 assumes an
‘‘exposed’’ configuration where it can bind to its receptor,
ICAM-1, on vascular endothelial cells. In contrast, when LFA-
1 is in the inactive state, the molecule is tucked in and unable
to bind to ICAM-1 (Carman and Springer, 2003). Binding of
active LFA-1 to ICAM-1 signals the WBC to travel into the
surrounding tissue (Hogg et al., 1993; Giblin and Lemieux,
2006). The LFA-1/ICAM-1 interaction has an important role in
the healthy immune response because it allows activated
WBCs to be called upon by cytokines when needed during
infection or injury. However, when LFA-1 is excessively
active or overexpressed on the surface of WBCs, there is an
accumulation of activated WBCs in the associated tissue,
which can result in autoimmune disease and inflammatory
disorders (Pals et al., 1989; McMurray, 1996; Engelhardt,
2006), such as AA.
TARGETING THE IMPOSTERS
One therapeutic strategy to target the activated WBCs in
autoimmune disease and inflammation is to use inhibitors of
LFA-1, which block the binding of LFA-1 to ICAM-1 (Weitz-
Schmidt et al., 2001; Yusuf-Makagiansar et al., 2002; Kvist
et al., 2008; Badell et al., 2010; Pilat et al., 2012). Blocking
this LFA-1/ICAM-1 interaction prevents the migration of
activated WBCs into the tissue from the blood stream. Thus,
there is an accumulation of WBCs in the peripheral blood,
also known as leukocytosis (Vugmeyster et al., 2004; Koszik
et al., 2010). One drawback to this strategy is that once
the blocking agent is depleted, the activated WBCs are free
to bind ICAM-1 and migrate back into the tissue. Thus,
patients need to be maintained on the drug continuously in
order for the serum levels to remain high enough to have a
pharmacological response. Indeed, the anti-LFA-1 monoclonal
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antibody, efalizumab (Raptiva), was administered to patients
weekly for treatment of psoriasis (Jullien et al., 2004;
Krueger et al., 2008). Similarly, drugs that just block a
component of the immune system, such as tumor necrosis
factor-a inhibitors, are also given to patients on a regular basis
for the treatment of autoimmune diseases and inflammatory
disorders.
An alternate strategy for treating immune-mediated disor-
ders is to deplete the cells that are involved in the condition.
An advantage of this approach over the use of blocking agents
is that frequent dosing is often not required since the disease-
related cells are eliminated rather than just transiently and
incompletely blocked. This depletion approach is also more
robust because treatment eliminates the source of inflamma-
tion, and thereby targets an earlier step of the pathogenic
process. An example of such a therapy is rituximab (rituxan),
which depletes B cells and is approved for treating patients
with rheumatoid arthritis (Goldblatt and Isenberg, 2008;
Dorner et al., 2009a, 2009b). Patients are maintained on
rituximab by dosing them once every 6 months.
A new experimental therapeutic that is able to deplete a
subset of WBCs is leukotoxin (LtxA; Leukothera). LtxA is a
natural protein that is derived from a bacterium (Aggregati-
bacter actinomycetemcomitans) found in the mouth of
humans (Kachlany, 2010). The protein has a natural
specificity for WBCs because its receptor is LFA-1 (Lally
et al., 1997, 1999). Furthermore, we have shown that LtxA
binds preferentially to the active form of LFA-1, thus
eliminating only the most activated WBCs in the body, and
not resting WBCs (Hioe et al., 2011; Stenderup et al., 2011;
DiFranco et al., 2012; Gupta et al., 2015).
We have reported very significant efficacy and safety of
LtxA in numerous animal models of disease. In humanized
mouse models for leukemia (Kachlany et al., 2010) and
lymphoma (Difranco et al., 2015), LtxA is able to eliminate
the cancer with only a few doses, and the cancer never
returns. We have also shown that LtxA is highly effective at
treating psoriasis in a human xenograft mouse model
(Stenderup et al., 2011). LtxA caused more significant
benefit than efalizumab for all parameters that were
measured, including thickness of the skin, clinical psoriasis
score, and lymphocyte infiltration. We recently published that
LtxA also provides significant therapeutic benefit in a mouse
model for allergic asthma (Gupta et al., 2015). Mice that are
administered house dust mite intranasally develop pulmonary
inflammation and symptoms resembling allergic asthma.
Administration of LtxA caused nearly complete reduction of
the WBCs (monocytes) that infiltrated the lung tissue as well as
a significant decrease in pulmonary inflammatory cytokines,
and these effects were more pronounced than with
dexamethasone, the most potent steroid that is clinically
available (Gupta et al., 2015).
When administered to rodents, dogs, and non-human
primates, LtxA causes a very rapid (within minutes) drop in
a subset of WBCs; and within a few hours, the WBC counts
return to starting values (Kachlany et al., 2010; DiFranco et al.,
2013). The replenishment of peripheral blood WBCs is likely
due to the migration of cells from the tissue back into the
blood stream. This effect provides yet another beneficial
mechanism by which LtxA works. Therefore, in addition to
eliminating the most activated, pro-inflammatory WBCs from
the peripheral blood, LtxA also draws in the activated WBC
population that resides in the tissue where they are causing the
inflammation and damage. Importantly, severe adverse
reactions have thus far not been observed in any of the
species in which LtxA has been evaluated. Thus, because LtxA
does not distinguish between cell type per se, but rather the
activation state of LFA-1, the therapy eliminates all of the cell
types implicated in disease; allowing a more comprehensive
approach (Figure 1).
While the immune system is clearly targeted by LtxA, there
has been no evidence that LtxA causes detrimental immuno-
suppression mainly because (1) the agent is so selective that it
targets only the activated component of the immune system
and (2) the observed effects on WBCs are transient and
reversible. Thus, LtxA only ‘‘subdues’’ the immune response
while it eliminates those cells most relevant for disease.
Indeed, targeting immune cells is inevitable if one wishes to
treat a condition in which the immune system is the primary
culprit.
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Figure 1. Current targeted therapies for WBC disorders affect a single
component of the immune system, such as a cell type or a specific cytokine
(top). Because the immune system is redundant, blocking only one component
is not always the most effective strategy for treating autoimmune and
inflammatory conditions, which are multifaceted. In contrast, LtxA
(Leukothera) targets the WBCs that are highly activated and most relevant for
disease (bottom). This approach eliminates the source of the cytokines, which
are responsible for driving the inflammatory process.
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MECHANISMS OF LtxA-MEDIATED CELL DEATH
Studies on the mechanism in which LtxA kills activated WBCs
have resulted in numerous interesting and novel revelations.
LtxA kills various cell types in different ways, depending on
the machinery that is available in the cells. For example, the
agent kills malignant and activated monocytes by binding to
LFA-1, being internalized by vesicle formation, and then being
transported to the lysosome where it causes lysosomal
damage, rearrangement of the actin cytoskeleton, and raid
cell death (DiFranco et al., 2012; Kaur and Kachlany, 2014).
LtxA can also activate the inflammasome in human
monocytes, which results in the release of cytokines and
pro-inflammatory cell death (Kelk et al., 2011). In malignant
and activated lymphocytes, in addition to LFA-1, LtxA requires
the cell death receptor Fas (CD95) and caspase 8, but does not
signal via the traditional FasL pathway (Difranco et al., 2015).
Activation of Fas then leads to the release of cytochrome c
from the mitochondrial intermembrane space and activation
of caspases 3, 7, and 9 (Lally et al., 1999; Yamaguchi et al.,
2001). Hence, even within a single cell type, numerous
pathways of cell death appear to be activated by LtxA,
which ensures the terminal fate of the cell.
LtxA AND AA
An effective treatment for AA should ideally act rapidly and
without significant side effects. LtxA can be administered
intravenously or subcutaneously and would eliminate the
‘‘rogue’’ activated WBC population very efficiently from
patients. It is not clear how frequently LtxA would have to
be given to provide benefit, but based on its mechanisms of
action and the dosing regimens of other drugs that deplete
cells, it is likely that frequent dosing would not be required. In
addition to systemic administration, local administration in the
form of intradermal injections or topical formulations is also
very possible with LtxA. Ultimately, clinical trials would be
required to identify the ideal formulation and dosing schedule
for treating AA with LtxA-based products.
FUTURE DIRECTIONS
To determine the potential applicability of LtxA for the
treatment of AA, future studies should include both in vitro
and in vivo experimentation. It would be interesting to
determine if patients with AA have increased expression of
the LFA-1 genes and proteins compared with non-affected
individuals. With the availability of the gene expression data
from these populations (Petukhova and Christiano, 2013; Betz
et al., 2015), this study is highly feasible. It would also be
revealing to perform histopathological analysis with AA hair
follicle tissue samples for detection of LFA-1 on the surface of
the WBCs that constitute the ‘‘swarm of bees’’. This in situ
data would demonstrate that the implicated WBCs could be
targets for LtxA. Indeed, early evidence already suggests that
LFA-1 is highly expressed on the cells that infiltrate the
affected skin in AA patients (Ghersetich et al., 1996).
Finally, LtxA should be evaluated in the mouse model for
AA that has recently been used successfully to study other
therapeutics (Katikaneni et al., 2013; Xing et al., 2014).
Positive results in one or more of these studies would allow
the continued development of LtxA as a potent and safe anti-
inflammatory therapy for the treatment of AA.
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